START-MET HS Prostate Cancer. : SbrT & Androgen Receptor Therapy METastatic HSPC
START-MET HS Prostate Cancer. : SbrT & Androgen Receptor Therapy METastatic HSPC
Recruiting · NCT05209243 · Registry updated 2023-05-19Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| START-MET HS Prostate Cancer. : SbrT & Androgen Receptor Therapy METastatic HSPC | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Not applicable | 2023-05-19 | NCT05209243 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic | 4 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Hospital Universitari i Politècnic La Fe | Valencia | Spain | 19 |
| Hospital Universitario Ramón y Cajal | Madrid | Spain | 87 |